Transcriptional Regulation of Solute Carrier Drug Transporters
Authors:
- 29 May 2022
- journal article
- review article
- Published by Elsevier in Drug Metabolism and Disposition
- Vol. 50 (9) , 1238-1250
Abstract
Facilitated transport is necessitated for large size, charged, and/or hydrophilic drugs to move across the membrane. The drug transporters in the solute carrier (SLC) superfamily, mainly including organic anion-transporting polypeptides, organic anion transporters, organic cation transporters, organic cation/carnitine transporters, peptide transporters, and multidrug and toxin extrusion proteins, are critical facilitators of drug transport and distribution in human body. The expression of these SLC drug transporters is found in tissues throughout the body, with high abundance in the epithelial cells of major organs for drug disposition such as intestine, liver, and kidney. These SLC drug transporters are clinically important in drug absorption, metabolism, distribution, and excretion. The mechanisms underlying their regulation have been revealing in recent years. Epigenetic and nuclear receptor–mediated transcriptional regulation of SLC drug transporters has particularly attracted much attention. This review focuses on the transcriptional regulation of major SLC drug transporter genes. Revealing the mechanisms underlying the transcription of these critical drug transporters will help us understand pharmacokinetics and pharmacodynamics, ultimately improving drug therapeutic effectiveness while minimizing drug toxicity. SIGNIFICANCE STATEMENT It has become increasingly recognized that solute carrier drug transporters play a crucial and sometimes determinative role in drug disposition and response, which is reflected in decision making during not only clinical drug therapy but also drug development. Understanding the mechanisms accounting for the transcription of these transporters is critical to interpret their abundance in various tissues under different conditions, which is necessary to clarify the pharmacological response, adverse effects, and drug-drug interactions for clinically used drugs.Keywords
This publication has 187 references indexed in Scilit:
- Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADMEArchives of Toxicology, 2013
- OATPs, OATs and OCTs: the organic anion and cation transporters of theSLCOandSLC22Agene superfamiliesBritish Journal of Pharmacology, 2012
- SLC22A5/OCTN2 expression in breast cancer is induced by estrogen via a novel intronic estrogen-response element (ERE)Breast Cancer Research and Treatment, 2012
- Alterations in Hepatic mRNA Expression of Phase II Enzymes and Xenobiotic Transporters after Targeted Disruption of Hepatocyte Nuclear Factor 4 AlphaToxicological Sciences, 2010
- Colon OCTN2 Gene Expression Is Up-regulated by Peroxisome Proliferator-activated Receptor γ in Humans and Mice and Contributes to Local and Systemic Carnitine HomeostasisJournal of Biological Chemistry, 2010
- Membrane transporters in drug developmentNature Reviews Drug Discovery, 2010
- Identification and characterization of novel polymorphisms in the basal promoter of the human transporter, MATE1Pharmacogenetics and Genomics, 2009
- ANIT-Induced Intrahepatic Cholestasis Alters Hepatobiliary Transporter Expression via Nrf2-Dependent and Independent SignalingToxicological Sciences, 2009
- Critical Role of PPAR-α in Perfluorooctanoic Acid– and Perfluorodecanoic Acid–Induced Downregulation of Oatp Uptake Transporters in Mouse LiversToxicological Sciences, 2008
- Tissue distribution, ontogeny and induction of the transporters Multidrug and toxin extrusion (MATE) 1 and MATE2 mRNA expression levels in miceLife Sciences, 2008